Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Regulatory Reads, January 2018: Brexit And New Reg-Deadline Minefields

Executive Summary

2018 has had a bumpy start in the realm of EU regulations. The tangled Brexit issue has some in industry playing Russian roulette, while other deadlines are causing concerns. These issues and more were covered in the most popular Medtech Insight EU regulation stories from January.

You may also be interested in...



Revolutionary EU HTA Cooperation Proposal Will Use MDR/IVDR Platforms

The European Commission wants to rationalize health technology assessment work across the EU, and new EU medtech regulations offer an easy way to determine which products can benefit from joint clinical assessments.

Prepping For Brexit With Notified Body Switch Could Be Unnecessary Expense, BSI Warns

While there are some warnings that UK medical device companies should be jumping ship, and taking worst-case Brexit scenarios seriously, major notified body BSI believes there is too much scaremongering, and that a less disruptive EU-UK agreement is likely.

Deadline Confusion Raised Over EU's Up-Classified, Low-Risk Products

A recently published clarification on deadlines for meeting the EU new Medical Device Regulations leaves open one critical question: Can low-risk products being up-classified benefit from a compliance extension?

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122159

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel